BIS outlines how pharmaceutical companies can seek company-specific onshoring agreements to reduce new 100% Section 232 tariffs on patented drugs and ingredients.
| less than a minute read
BIS Issues Procedures for Onshoring Agreements to Mitigate 100% Tariffs on Patented Pharmaceuticals
Get in touch
Get in touch
Get in touch
Get in touch
Latest Insights
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-11-13-18-15-09-670-6af753ad66780e8d44b961dc.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-11-13-18-16-58-397-6af7541af95e46da249947b9.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-11-13-18-17-30-474-6af7543af95e46da24994885.jpg)